Print this page
Home | Tranfection Reagents | IN VIVO DELIVERY | in vivo nucleic acid delivery : in vivo-jetPEI®
Back to products list

in vivo nucleic acid delivery: in vivo-jetPEI®

The easiest delivery method for in vivo proof of concept.
  • Deliver DNA, siRNA, miRNA and oligonucleotides in vivo
  • Simple/easy to use: Just mix and administer
  • Used for therapeutics and clinical trials worldwide
  • Safe: no inflammatory response
  • Help at hand with Polyplus experts

in vivo-jetPEI® is a powerful polymer based reagent used to deliver any nucleic acid to any animal model. The protocol is similar to a classical transfection: just mix and administer.

in vivo-jetPEI® forms stable complexes with the nucleic acid, protecting it from degradation and thus facilitating in vivo delivery.

With a proven track record (over 200 Publications), in vivo-jetPEI® has already been used to target many organs using many administration routes.

EXCLUSIVE LICENSE:
The use of polyethylenimine (PEI) or polypropylenimine (PPI) or cationic polymers similar in structure thereto for transfecting cells, as well as compositions comprising these cationic polymers and at least one nucleic acid, are the subject matter of U.S. Patent No. 6,013,240, EP Patent No. 0770140 and foreign equivalents, for which Polyplus-transfection® is the worldwide exclusive licensee.

More information:

Expand All Tabs
Catalog Number Amount of reagent Amount of glucose solution
201-10G 0.1 ml 10 ml
201-50G 0.5 ml 2 x 10 ml
With 0.1ml of in vivo-jetPEI® perform up to 20 intravenous injections in mouse with 50 µg of nucleic acid. The glucose solution is required to form nucleic acid/in vivo-jetPEI® complexes adapted to in vivo injections. Bulk quantities and GMP grade are available upon request. Please contact us.

 

« I finished the experiments and I think in vivo-jetPEI works great. I am very pleased with the results. Actually some of the work we have done with in vivo-jetPEI as well as jetSI has been published in Science. I would like to tell you that I am also very pleased with the technical assistance. Many thanks! » – Emine E.K.

« Our project is going quite well, we are working a lot with your siRNAs delivery system, and we are obtaining superb results in vivo. » – Mattia C.

« The Polyplus system worked wonderfully in vivo. » – Eduardo D.

« in vivo-jetPEI is a very nice reagent to work with! » – Marie-Line G.

« We did a preliminary trial with in vivo-jetPEI and a luciferase construct delivered into the ventricle of a cannulated mouse and it worked great! » – Cristina M.

 

in vivo-jetPEI® is the reagent of choice to deliver any type of nucleic acids to mediate gene expression or gene silencing in various tissues. The success of this delivery system relies on the ability to efficiently deliver the appropriate therapeutic nucleic acid into the target tissue or cells with low toxicity and limited immune response.

in vivo-jetPEI® is very versatile as it is suitable for plasmid DNA, siRNA, shRNA, miRNA, oligonucleotides…

Image 5 Plasmid delivery: Protein expression following systemic delivery using in vivo-jetPEI® in mice. Experimental conditions: Bioluminescent imaging of luciferase expression in living Nude mouse using IVIS 100 camera (Caliper-PerkinElmer) 24 h after gene delivery. pCMVLuc (50 µg) was complexed with in vivo-jetPEI® in 400 µl of 5% glucose solution and injected into the tail vein.
Fig3 siRNA CTL siRNA mediated silencing: 90 % inhibition of protein expression using in vivo-jetPEI® in mice.

Experimental conditions: Co-transfection of pCMVLuc (40 µg) with 10 siRNA (upper : control; lower anti-Luc siRNA ). The complexes were injected via the tail vein of nude mice and luciferase gene expression was monitored in living mice 24 h later by bioluminescence imaging using a cooled CCD camera.

Fig3 siRNA Luc

Browse the literature for administration routes and organs targeted with your nucleic acid.

PDFPublications by administration route

PDFPublications by targeted organ

PDFBioimaging of Gene Delivery with in vivo-jetPEI®

 

The protocol is fast and simple: prepare separately the nucleic acid and in vivo-jetPEI® in 5% glucose, mix and incubate 15 min at RT, then inject the nucleic acid/ in vivo-jetPEI® complexes into the animal. This protocol is suitable for any administration route and any animal model.

Protocol for in vivo-jetPEI®

Fig1 in vivo-jetPEI™ protocol total

 

The stability of in vivo-jetPEI® nucleic acid complexes allows the use of numerous routes of administration including systemic injection or topical application.

Examples of delivery routes using in vivo-jetPEI® in mice.

invivo-jetPEI-fig2

The route of administration largely determines the targeted organ. For example upon intravenous injection, in vivo-jetPEI®-mediated DNA delivery leads to gene expression mainly in the lung but also in the liver, pancreas, spleen, kidney, heart, bladder and artery.

Image 1 Experimental conditions :  pCMVLuc (50 µg) was complexed with in vivo-jetPEI® in 400 µl of 5% glucose solution and injected into the tail vein. 24 h after gene delivery organs were extracted and luciferase level in each organ was analysed using a luciferase assay and expressed relative to the amount of total proteins.

PDFPublications by Administration Route

in vivo-jetPEI® is also suitable for local delivery routes such as topical application,  intracerebral or intra-articular injections, and it is perfect for nucleic acid delivery into subcutaneous tumor models.

Other targeted organs include the brain, liver, pancreas, spleen, kidney, heart, bladder, skin, retina, artery, etc.

PDFPublications by Targeted Organ

Get Expert help for faster results: Our delivery specialists are available to adapt our protocol to your specific application and send you the relevant literature (Please contact the technical support team).  You may also download the guidelines and protocols for in vivo experiments in mice.

PDFGuidelines for Delivery in Mice

PDFPROTOCOL

 

in vivo-jetPEI® is ideal for nucleic acid delivery in mice.

The protocol is so easy and versatile that it has been adapted to many other species including rat, guinea pig, hamster, dog, rabbit, monkey, goat, sheep, cow, marmot, chicken, quail, duck, pigeon, gecko, tadpole, shrimp,  zebrafish, abalone, snail, leech, mosquito…

Get expert help for faster results: Our delivery experts are available to help adapt our protocol to your animal model and send you the relevant literature (Please contact the technical support team).

 

Following in vivo-jetPEI® -mediated systemic delivery of nucleic acid, there is no induction of major pro-inflammatory cytokines and no increase in sera levels of hepatic enzymes (Bonnet et al. (2008), Pharm Res, 25:2972). Hence, in vivo-jetPEI® offers a reliable and safe alternative to viral vectors that can elicit an immune response.

immune response siRNA Pro-inflammatory cytokines concentration following IV delivery of nucleic acid/in vivo-jetPEI®. Experimental conditions: 40 ug siRNA were delivered with or without in vivo-jetPEI®.TNF-α, IL12/IL23, IFNγ and IL6  were measured 1h, 6h, 12h and 6 h after delivery respectively. The negative control is glucose only, the positive control a 50 μg IP injection of E.Coli LPS

 

in vivo-jetPEI® has been selected as a delivery vector for several drug development programs due to its safety and delivery efficiency. There are currently several ongoing phase I and II clinical trials for cancer therapies, heart disease, traumatic brain injury and HIV immune gene therapy using in vivo-jetPEI®.

As an example of the use of Polyplus’ transfection® reagents in a cell therapy trial please visit the OHRI website in Canada.

Clinical pipeline: Ongoing clinical trials using in vivo-jetPEI®
schema clinical pipe_Polyplus customers February 2015

 

Complexes formed between nucleic acids and in vivo-jetPEI® do not form aggregates over time and thus are stable for at least 24 h at RT, 4 °C and 37 °C.

With stable complexes, the nucleic acid is protected for longer, thereby allowing the preparation of complexes in advance or the use of osmotic pumps for a continuous delivery.

Image 2 Experimental protocol : pCMVLuc (40 µg) was complexed with in vivo-jetPEI®. Complexes incubated for 30 min or 24 h at 4 °C were intravenously injected. Animals were imaged using IVIS100 bioimaging system (Caliper-PerkinElmer) 24 h after injection.

For more details, download the Bioimaging application note.

 

Tumour growth inhibition following in vivo-jetPEI® based nucleic acid delivery

In vivo gene silencing and tumor growth inhibition:

Lung tumour metastasis inhibition in mice treated with modified siRNA delivered with in vivo-jetPEI®

Image 3 Experimental conditions: Mice were injected intravenously with TSA-Luc cells forming exclusively lung metastases. 2 days after cell injection, the mice were treated with 1 mg/kg of STICKY siRNATM against cyclin B1 (N/P=12.5). Bioluminescence imaging was performed 10 days after cell injection. Data from Bonnet et al., (2013), J Control Release 170(2) :183-90

Tumor xenograft growth inhibition in mice treated with modified siRNA delivered with in vivo-jetPEI®

Image 4 Experimental conditions: Mice were injected intravenously with TSA-Luc cells forming exclusively lung metastases. 2 days after cell injection, the mice were treated with 1 mg/kg of STICKY siRNATM against cyclin B1 (N/P=12.5). Bioluminescence imaging was performed 10 days after cell injection. Data from Bonnet et al., (2013), J Control Release 170(2) :183-90

For other example targeting tumors see

Publication list by target organs Or Polyplus Litterature search

 

In order to improve siRNA delivery in vivo, Polyplus transfection has developed a novel type of siRNA. By including longer overhangs within the siRNA, we have generated STICKY siRNA™ (ssiRNA) that are able to form concatemers in the presence of in vivo-jetPEI®, thereby mimicking the structure of DNA and thus enhancing siRNA transfer. This was shown to improve in vitro siRNA delivery and gene silencing efficiency (Bolcato-Bellemin (2007), PNAS 104:16050). We have also shown that intraperitoneal injection of STICKY siRNA™ cyclinB1 in mice using in vivo-jetPEI® in a PC-3 tumor model, lead to an inhibition of tumor metastasis compared to mismatch and control. Moreover, mice survival is increased dramatically with STICKY siRNA™ delivered by in vivo-jetPEI®.

plus-bleuFor more information see STICKY SIRNA™